当前位置:
X-MOL 学术
›
Org. Process Res. Dev.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
MGAT2 临床候选药物 BMS-963272 的合成优化、放大和催化剂筛选工作
Organic Process Research & Development ( IF 3.1 ) Pub Date : 2022-03-24 , DOI: 10.1021/acs.oprd.2c00036 James Kempson 1 , Xiaoping Hou 1 , Jung-Hui Sun 1 , Michael Wong 1 , Joseph Pawluczyk 1 , Jianqing Li 1 , Subramaniam Krishnananthan 1 , Eric M. Simmons 2 , Yi Hsiao 2 , Yi-Xin Li 1 , Dawn Sun 1 , Dauh-Rurng Wu 1 , Wei Meng 1 , Saleem Ahmad 1 , Lidet Negash 1 , Robert Brigance 1 , Huji Turdi 1 , Jon J. Hangeland 1 , R. Michael Lawrence 1 , Pratik Devasthale 1 , Jeffrey A. Robl 1 , Arvind Mathur 1
Organic Process Research & Development ( IF 3.1 ) Pub Date : 2022-03-24 , DOI: 10.1021/acs.oprd.2c00036 James Kempson 1 , Xiaoping Hou 1 , Jung-Hui Sun 1 , Michael Wong 1 , Joseph Pawluczyk 1 , Jianqing Li 1 , Subramaniam Krishnananthan 1 , Eric M. Simmons 2 , Yi Hsiao 2 , Yi-Xin Li 1 , Dawn Sun 1 , Dauh-Rurng Wu 1 , Wei Meng 1 , Saleem Ahmad 1 , Lidet Negash 1 , Robert Brigance 1 , Huji Turdi 1 , Jon J. Hangeland 1 , R. Michael Lawrence 1 , Pratik Devasthale 1 , Jeffrey A. Robl 1 , Arvind Mathur 1
Affiliation
本文描述了1 (BMS-963272) 的有效放大合成,该合成依赖于高选择性曼尼希型烷基化策略以立体定向安装季碳中心。分子内环化反应也用于形成芳基二氢吡啶酮 (ADHP) 核心。已证明优化的路线可为临床前毒理学评估提供超过 100 g 的活性药物成分。作为互补收敛方法的一部分,还讨论了催化剂筛选工作,这将有助于更方便地评估在 ADHP 核心的 C4 位具有芳基多样性的备用分子。
"点击查看英文标题和摘要"
更新日期:2022-03-24
"点击查看英文标题和摘要"